about
Quality of life in Parkinson's diseaseEffects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvaeBehavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury.Social phobia in Parkinson's disease: Prevalence and risk factorsExercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse.Psychiatric aspects of Parkinson's disease.Neuropsychiatric non-motor aspects of Parkinson's disease.Impact of anxiety on quality of life in Parkinson's disease.Neurocognitive correlates of apathy and anxiety in Parkinson's disease.Treatment of behavioural symptoms and dementia in Parkinson's disease.The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's DiseaseConceptualization of depression in Parkinson's diseaseIntervening in the neuropsychiatric features of Parkinson's disease.Reformulating psychological difficulties in people with Parkinson's disease: the potential of a social relational approach to disablism.Rodent models of Parkinson's disease: beyond the motor symptomatologyThe Effects of Physical Activity in Parkinson's Disease: A Review.Clinical Presentation of Anxiety in Parkinson's Disease: A Scoping Review.Cognitive Profiles in Parkinson's Disease and their Correlation with Dementia, Anxiety and Depression: A Preliminary Study.Anxiety disorders in Parkinson's disease: prevalence and risk factors.A Novel Approach to Treating Anxiety and Enhancing Executive Skills in an Older Adult with Parkinson's Disease.Obstacle Avoidance amongst Parkinson Disease Patients Is Challenged in a Threatening Context.MPTP-Induced Dopamine Depletion in Basolateral Amygdala via Decrease of D2R Activation Suppresses GABAA Receptors Expression and LTD Induction Leading to Anxiety-Like Behaviors.Lack of involvement of alpha-synuclein in unconditioned anxiety in mice.Behind the mask : a study on the clinical course, psychopathology and impact on quality of life in idiopathic Parkinson's disease.Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study.Anxiety disorders in Chinese patients with Parkinson's disease.Psychiatric comorbidity in a population of Parkinson's disease patients.Screening for anxiety symptoms in Parkinson disease: a cross-sectional study.The relation of anxiety and cognition in Parkinson's disease.Panic attack like episodes possibly associated with pramipexole therapy in Parkinson's disease.Coping processes and health-related quality of life in Parkinson's disease.Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice.Clinical Markers of Anxiety Subtypes in Parkinson Disease.Clinical practice guidelines for Geriatric Anxiety Disorders.
P2860
Q26849637-EB9B1234-EC84-4BD4-BF6E-74BDA680FBD8Q28468677-4B6A7118-C3AB-4A0E-9BEB-E7090D7684D3Q30454614-0279D60F-C8D2-465A-B1BA-1A8B9DC99D2FQ30470435-CB20D77E-7BAA-463E-BC6F-780D2129C4C4Q33726380-7E8A948F-497D-4D00-87DA-5E4ADC137080Q33987540-FC7C2D85-9468-46E5-8CEF-3A8B9EB85D07Q34574771-6133A0EA-05AD-4B10-B2AD-05403904F54EQ35518017-F9F5684A-E0C9-43EE-90F9-B72024583FB4Q35609023-ADB0C512-AED9-4E96-9E4A-396FFFE620C4Q35615127-28C9D071-2D04-4322-B049-CD30BB9725DDQ36089350-C5B37E5D-18AA-4B38-B33C-429630F9D5CBQ36494212-9C7BAEB0-6414-4F4B-9EE3-885A9BEC4C79Q36700296-4BC66072-76E7-46BB-A1D7-91A12ADD03DCQ36847266-93E6FBB7-4498-4A83-BF17-E8A777448B47Q37127123-BD1E6E4F-8434-4591-B911-1F63616A4F1DQ37343565-56EE99F1-7A70-43E7-9CD1-61922FF0AD56Q38938925-27997191-DE1F-4DF2-B2D5-26931B0E73AFQ38952143-6A14E3F8-4148-4053-A591-97A2045A6F82Q39091481-ADFBFCBA-6D10-40B9-A0FB-BA05D478FD2CQ39874201-2AFD9C68-A29F-4534-82C0-B76D755646BBQ40099576-ED0BB5F9-35CB-4E7C-B0DC-7AFD31DBBDD6Q40597095-9AFA6EAB-3397-462E-8B1D-B32EC6DB7AF5Q41269545-756DA570-E0F9-483A-B9B8-878AF83C92A0Q41881379-28000D0C-04E0-472A-AA49-2DB1ACB28B24Q42413314-2477CB97-EFDC-4F72-8FB4-A0D75BDF19F6Q43233198-ED3BA915-0468-487A-937E-FC5CECCFB394Q44191275-8D3089EC-80F2-4BB7-8E4A-F96CBFD5B159Q44895214-C1A50356-6966-4495-BAC1-50AF7E442304Q45735428-6BE902BF-A591-4154-84C6-5F19E072892AQ47744162-72E603DF-4C59-4C6D-9183-A1DB5D74D379Q48605970-4DBF10CA-E192-499F-9D2D-24A44BF66F2DQ49131297-65C848D0-51A6-4F38-A402-B83F81C0623AQ51839227-DCC71078-4E28-49C9-9B1E-03A3FA3D8137Q55077870-81606085-F14E-43EA-A505-8D5BC2345110Q55092075-A479109F-C8D1-450F-BADE-17F89F9233E2
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Parkinson's disease and anxiety
@ast
Parkinson's disease and anxiety
@en
Parkinson's disease and anxiety
@nl
type
label
Parkinson's disease and anxiety
@ast
Parkinson's disease and anxiety
@en
Parkinson's disease and anxiety
@nl
prefLabel
Parkinson's disease and anxiety
@ast
Parkinson's disease and anxiety
@en
Parkinson's disease and anxiety
@nl
P2860
P356
P1476
Parkinson's disease and anxiety
@en
P2093
P2860
P356
10.1136/PMJ.77.904.89
P407
P577
2001-02-01T00:00:00Z